Logo
x

Search

Subscribe Now

Maintenance

Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from VISIBLE OLE Study for Moderately to Severely Active Ulcerative Colitis

Takeda Reports Results of Entyvio (vedolizumab) in Interim Analysis from VISIBLE OLE Study for Moderately to Severely Active Ulcer...

  • October 13, 2020
Novartis' Enerzair Breezhaler Receives the EC's Approval as a Maintenance Treatment of Asthma in Adult Patients Uncontrolled with LABA/ICS

Novartis' Enerzair Breezhaler Receives the EC's Approval as a Maintenance Treatment of Asthma in Adult Patients Uncontrolled with...

  • July 7, 2020
Acacia Pharma's Byfavo (remimazolam) Receives the US FDA's Approval for the Induction and Maintenance of Procedural Sedation

Acacia Pharma's Byfavo (remimazolam) Receives the US FDA's Approval for the Induction and Maintenance of Procedural Sedation

  • July 2, 2020
AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastat...

  • December 30, 2019
GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer

GSK Reports Results of Zejula (niraparib) in P-III PRIMA Study as 1L Maintenance Therapy for Ovarian Cancer

  • July 15, 2019
Clovis Oncology's Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults

Clovis Oncology's Rubraca (Rucaparib) Receives EU Approval for Maintenance Treatment of Relapsed Ovarian Cancer (OC) in Adults

  • January 25, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.